$SRRA News

Last published 4y ago

4y agoCDXS SRRACodexis Announces CEO Transition Effective August 9, 2022GlobeNewswireDr. Stephen Dilly, Board member and biotechnology veteran, named the next President and CEOJohn Nicols to retire after ten years leading the transformation and growth of Codexis REDWOOD CITY, Calif., July 18, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc.
4y agoSRRASierra Oncology Announces Submission of New Drug Application for Momelotinib to US Food & Drug AdministrationBusiness Wire– Submission seeks approval of momelotinib for the treatment of myelofibrosis – Sierra Oncology, Inc. (NASDAQ:SRRA), a late-stage biopharmaceutical company on a mission to deliver transformative therapies for rare cancers, today announced the com
4y agoSRRAMomelotinib Pivotal Phase 3 Data Receives Oral Presentation at American Society of Clinical Oncology Annual MeetingBusiness Wire– MOMENTUM data demonstrate potential use of momelotinib in myelofibrosis patients who are symptomatic and anemic – – Additional data highlight improved transfusion independence, symptoms and spleen volume of cytopenic myelofibrosis patients ��
4y agoSRRASierra Oncology Announces Oral Presentation of Momelotinib Pivotal Phase 3 Data at European Hematology Association Annual MeetingBusiness Wire– Oral presentation of MOMENTUM pivotal phase 3 data in myelofibrosis patients who are symptomatic and anemic – – Poster presentation to highlight improved transfusion independence, symptoms and spleen volume of these myelofibrosis patients who
4y agoSRRASierra Oncology Reports First Quarter 2022 ResultsBusiness WireSierra Oncology, Inc. (NASDAQ:SRRA), a late-stage biopharmaceutical company with a mission to deliver targeted therapies that treat rare forms of cancer, today reported its financial and operating results for the first quarter ended March 31, 2022. "
4y agoSRRASierra Oncology Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)Business WireSierra Oncology, Inc. (NASDAQ:SRRA), a late-stage biopharmaceutical company dedicated to delivering targeted therapies for rare cancers, granted stock options to twelve new employees as approved by the Compensation Committee of the Company's Board of Di
4y agoSRRARayzeBio Appoints Angie You, Ph.D., to its Board of DirectorsBusiness WireRayzeBio, Inc., a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor targets, appointed Angie You, Ph.D., to its board of directors. Dr. You is a seasoned biotechnology executive and was recently the chi
4y agoATRS CLVS GSK ONCY+2Advancements of CAR-T Cell Therapies Importance Grows While Cancer Cases IncreasingPR NewswirePALM BEACH, Fla., April 14, 2022 /PRNewswire/ -- FinancialNewsMedia.com News Commentary - CAR-T therapy is a sort of treatment in which a patient's T cells which is a type of immune system cell, are genetically modified to attack cancer cells in the lab.
4y agoALZN ARTL BCTX SRRA+1Thinking about buying stock in Alzamend Neuro, Briacell Therapeutics, Sierra Oncology, Artelo Biosciences, or Veru?PR NewswireNEW YORK, April 13, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ALZN, BCTX, SRRA, ARTL, and VERU.
4y agoATRS BLK BBBY JPM+7Stocks making the biggest moves premarket: Delta, JPMorgan, BlackRock and moreCNBCThese are the stocks posting the largest moves before the bell.
4y agoGSK SRRAGSK Reaches Agreement to Acquire Late-Stage Biopharmaceutical Company Sierra Oncology For $1.9bnBusiness WireSierra Oncology's differentiated momelotinib has the potential to address the critical unmet medical needs of myelofibrosis patients with anaemia Momelotinib complements GSK's existing expertise in haematology, with Sierra Oncology anticipating US
4y agoSRRASierra Oncology Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)Business WireSierra Oncology, Inc. (NASDAQ:SRRA), a late-stage biopharmaceutical company dedicated to delivering targeted therapies for rare cancers, granted stock options to seven new employees as approved by the Compensation Committee of the Company's Board of Dir
4y agoSRRASierra Oncology to Participate in the Oppenheimer 32nd Annual Healthcare ConferenceBusiness WireSierra Oncology, Inc. (NASDAQ:SRRA), a late-stage biopharmaceutical company dedicated to delivering targeted therapies for rare cancers, today announced the company will participate in the 32nd Annual Oppenheimer Healthcare Conference being held virtual
4y agoSRRASierra Oncology Reports 2021 Year End ResultsBusiness Wire– Planned Q2 2022 NDA submission following positive topline data from MOMENTUM clinical trial of momelotinib in symptomatic and anemic myelofibrosis patients – – Financial position significantly strengthened – Sierra Oncology, Inc. (NASDAQ
4y agoSRRASierra Oncology Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)Business WireSierra Oncology, Inc. (NASDAQ:SRRA), a late-stage biopharmaceutical company dedicated to delivering targeted therapies that treat rare forms of cancer, granted stock options to six new employees as approved by the Compensation Committee of the Company's
4y agoSRRAFrazier Life Sciences Adds Highly Experienced Biopharmaceutical Executive to TeamBusiness WireFrazier Life Sciences announced the addition of Angie You, Ph.D. as a Senior Advisor. She most recently served as Chief Executive Officer of Amunix Pharmaceuticals Inc. until its acquisition by Sanofi for up to $1.225 billion. Prior to joining Amunix
4y agoSRRASierra Oncology Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)Business WireSierra Oncology, Inc. (NASDAQ:SRRA), a late-stage biopharmaceutical company on a mission to deliver targeted therapies that treat rare forms of cancer, granted a stock option to one new employee as approved by the Compensation Committee of the Company's
4y agoDB GRWG SAVE SRRA+1Thinking about buying stock in GrowGeneration, Teradata, Spirit Airlines, Deutsche Bank, or Sierra Oncology?PR NewswireNEW YORK, Feb. 8, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for GRWG, TDC, SAVE, DB, and SRRA. To
4y agoSRRASierra Oncology Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)Business WireSierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company on a mission to deliver targeted therapies that treat rare forms of cancer, granted a stock option to one new employee as approved by the Compensation Committee of the Company's Board
4y agoSRRASierra Oncology Announces Full Exercise of Underwriters' Option to Purchase Additional SharesBusiness WireSierra Oncology, Inc. (NASDAQ:SRRA), a late-stage biopharmaceutical company dedicated to delivering targeted therapies for rare cancers, today announced that the underwriters of its previously announced underwritten public offering exercised in full the
4y agoSRRASierra Oncology to Participate in Guggenheim Oncology ConferenceBusiness WireSierra Oncology, Inc. (NASDAQ:SRRA), a late-stage biopharmaceutical company dedicated to delivering targeted therapies for rare cancers, today announced the company will participate in the 4th Annual Guggenheim Oncology Conference being held virtually f
4y agoSRRASierra Oncology Announces Closing of Upsized Public Offering of $135.0 Million of SecuritiesBusiness WireSierra Oncology, Inc. (NASDAQ:SRRA), a late-stage biopharmaceutical company dedicated to delivering targeted therapies for rare cancers, today announced the closing of its previously announced underwritten public offering of 4,074,075 shares of its comm
4y agoHZO IO PIXY SRRA+1Thinking about buying stock in Sierra Oncology, ShiftPixy, Sasol, MarineMax, or Ion Geophysical?PR NewswireNEW YORK, Jan. 27, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SRRA, PIXY, SSL, HZO, and IO. To
4y agoBMY MRK ONCY SRRA+1R&D Spending Increases Exponentially for Higher Standard of Breast Cancer Drug TreatmentsPR NewswirePALM BEACH, Fla., Jan. 27, 2022 /PRNewswire/ -- FinancialNewsMedia.com News Commentary - According to International Agency for Research on Cancer (IARC) published by the World Health Organization (WHO) in 2018, breast cancer ranks as the fifth leading c
4y agoSRRASierra Oncology to Present at B. Riley Securities Oncology Investor ConferenceBusiness WireSierra Oncology, Inc. (NASDAQ:SRRA), a late-stage biopharmaceutical company dedicated to delivering targeted therapies for rare cancers, today announced the company will participate in the 2022 B. Riley Securities Oncology Investor Conference being held
4y agoSRRASierra Oncology Announces Pricing of Upsized Public Offering of SecuritiesBusiness WireSierra Oncology, Inc. (NASDAQ:SRRA), a late-stage biopharmaceutical company dedicated to delivering targeted therapies for rare cancers, today announced the pricing of an upsized underwritten public offering of 4,074,075 shares of its common stock and,
4y agoSRRASierra Oncology Announces Proposed Public Offering of Common StockBusiness WireSierra Oncology, Inc. (NASDAQ:SRRA), a late-stage biopharmaceutical company dedicated to delivering targeted therapies for rare cancers, today announced that it intends to offer and sell $100.0 million of shares of its common stock in an underwritten pu
4y agoAMRN ERIC MDRX SDC+1Thinking about buying stock in Sierra Oncology, Allscripts Healthcare Solutions, SmileDirectClub, Ericsson, or Amarin Corp?PR NewswireNEW YORK, Jan. 25, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SRRA, MDRX, SDC, ERIC, and AMRN.
4y agoSRRASierra Oncology Provides Financial Update to Support the Future Commercialization of MomelotinibBusiness Wire—Oxford Finance Debt Facility for up to $125 Million— —Series B Warrants Will Expire in 75 Days, and if Fully Exercised, Could Provide An Additional $33.3 Million— Sierra Oncology, Inc. (NASDAQ:SRRA), a late-stage biopharmaceutical company
4y agoSRRASierra Oncology Announces Momelotinib Achieved Statistically Significant Benefit on Symptoms, Anemia and Splenic Size in the Pivotal MOMENTUM Study for MyelofibrosisBusiness Wire—New Drug Application submission planned for second quarter of 2022— —Full data set to be presented at an upcoming medical meeting— Sierra Oncology, Inc. (NASDAQ:SRRA), a late-stage biopharmaceutical company dedicated to delivering targete
4y agoSRRAMomelotinib Review Article Published in Journal of Hematology & Oncology Highlights Importance of Anemia Benefit for Myelofibrosis PatientsBusiness WireSierra Oncology, Inc. (NASDAQ:SRRA), a late-stage biopharmaceutical company dedicated to delivering targeted therapies for rare cancers, today announced the publication of a review article in the Journal of Hematology & Oncology that outlines the potent
4y agoSRRASierra Oncology Updates Topline Data Timing for Pivotal Phase 3 Trial of Momelotinib in MyelofibrosisBusiness Wire—Company now anticipates MOMENTUM topline data readout by the end of January 2022— Sierra Oncology, Inc. (NASDAQ:SRRA), a late-stage biopharmaceutical company dedicated to delivering targeted therapies for rare cancers, today announced it has sho
4y agoSRRASierra Oncology Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)Business WireSierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company dedicated to delivering targeted therapies for rare cancers, granted stock options to nine new employees as approved by the Compensation Committee of the Company's Board of Directors,
4y agoSRRASierra Oncology to Present at HC Wainwright BioConnect ConferenceBusiness WireSierra Oncology, Inc. (NASDAQ:SRRA), a late-stage biopharmaceutical company dedicated to delivering targeted therapies for rare cancers, today announced the company will participate in the 2022 HC Wainwright BioConnect Conference being held virtually fr
4y agoSRRASierra Oncology Reports Baseline Ferritin Differentially Predicts Week 24 Transfusion Independence Response in Myelofibrosis PatientsBusiness WireSierra Oncology, Inc. (NASDAQ:SRRA), a late-stage biopharmaceutical company on a mission to deliver targeted therapies that treat rare forms of cancer, today announced data from new retrospective analyses of the Phase 3 SIMPLIFY studies demonstrate base
4y agoSRRASierra Oncology Announces Investor Event to Review MOMENTUM Trial Design and Available Phase 3 Momelotinib Data in MyelofibrosisBusiness Wire—Topline data expected by February 2022— —Prithviraj Bose, MD, to join Sierra Oncology Leadership to discuss importance of treating anemia in myelofibrosis patients— Sierra Oncology, Inc. (NASDAQ:SRRA), a late-stage biopharmaceutical compa
4y agoSRRASierra Oncology Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)Business WireSierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company on a mission to deliver targeted therapies that treat rare forms of cancer, granted stock options to six new employees as approved by the Compensation Committee of the Company's Board
5y agoSRRASierra Oncology Announces Presentation at Jefferies London Healthcare ConferenceBusiness WireSierra Oncology, Inc. (NASDAQ:SRRA), a late-stage biopharmaceutical company on a mission to deliver targeted therapies that treat rare forms of cancer, today announced the company will participate in the 2021 Jefferies London Healthcare Conference. Step
5y agoORIC SRRAORIC Pharmaceuticals Appoints Angie You, Ph.D., to its Board of DirectorsGlobeNewswireSOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 10, 2021 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced
5y agoSRRASierra Oncology Reports Third Quarter 2021 ResultsBusiness Wire– MOMENTUM study on track for topline data read-out by February 2022 – – Global in-licensing deal expands myelofibrosis pipeline and provides options for combination studies in other hematologic malignancies and solid tumors – Sierra Oncol
5y agoSRRASierra Oncology Announces Momelotinib Poster Accepted for Presentation at ASHBusiness WireSierra Oncology, Inc. (NASDAQ:SRRA), a late-stage biopharmaceutical company on a mission to deliver targeted therapies that treat rare forms of cancer, today announced new retrospective analyses of the momelotinib Phase 3 SIMPLIFY studies will be presen
5y agoSRRASierra Oncology Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)Business WireSierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company on a mission to deliver targeted therapies that treat rare forms of cancer, granted stock options to three new employees as approved by the Compensation Committee of the Company's Boar
5y agoSRRASierra Oncology Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)Business WireSierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company on a mission to deliver targeted therapies that treat rare forms of cancer, granted stock options to two new employees as approved by the Compensation Committee of the Company's Board
5y agoSRRASierra Oncology to Present at Three September Investor ConferencesBusiness WireSierra Oncology, Inc. (NASDAQ:SRRA), a late-stage biopharmaceutical company on a mission to deliver targeted therapies that treat rare forms of cancer, today announced the company will participate in three investor conferences in September 2021. Stephen
5y agoSRRASierra Oncology Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)Business WireSierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company on a mission to deliver targeted therapies that treat rare forms of cancer, granted stock options to five new employees as approved by the Compensation Committee of the Company's Board
5y agoSRRASierra Oncology Provides Update to Momelotinib Development Timeline and Closes on $34 Million in Additional FundingBusiness WireSierra Oncology, Inc. (NASDAQ:SRRA), a late-stage biopharmaceutical company on a mission to deliver targeted therapies that treat rare forms of cancer, today updated guidance on the development timeline for its lead product candidate, momelotinib. The c
5y agoAZN SRRASierra Oncology Signs Exclusive Global In-Licensing Agreement with AstraZeneca for Novel BET Inhibitor to Expand Myelofibrosis PipelineBusiness Wire—Combination study to build upon momelotinib's differentiated potential as a cornerstone myelofibrosis therapy-— Sierra Oncology, Inc. (NASDAQ:SRRA), a late-stage biopharmaceutical company on a mission to deliver targeted therapies that treat r
5y agoSRRASierra Oncology Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)Business WireSierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company on a mission to deliver targeted therapies that treat rare forms of cancer, granted stock options to three new employees as approved by the Compensation Committee of the Company's Boar
5y agoSRRASierra Oncology Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)Business WireSierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company on a mission to deliver targeted therapies that treat rare forms of cancer, granted a stock option to a new employee as approved by the Compensation Committee of the Company's Board of
5y agoSRRASierra Oncology Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)Business WireSierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company on a quest to deliver targeted therapies that treat rare forms of cancer, granted stock options to five new employees as approved by the Compensation Committee of the Company's Board o